BiotechTube

BMN165 20mg/day + BMN165 40mg/day + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria (PKU)

Conditions

Phenylketonuria (PKU)

Trial Timeline

Jul 29, 2013 → Feb 5, 2019

NCT ID
NCT01889862

About BMN165 20mg/day + BMN165 40mg/day + Placebo

BMN165 20mg/day + BMN165 40mg/day + Placebo is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria (PKU). The current trial status is completed. This product is registered under clinical trial identifier NCT01889862. Target conditions include Phenylketonuria (PKU).

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01889862Phase 3Completed

Competing Products

20 competing products in Phenylketonuria (PKU)

See all competitors
ProductCompanyStageHype Score
SYNB1934v1 + PlaceboSynlogicPhase 3
69
SYNB1618 + PlaceboSynlogicPhase 1/2
33
SYNB1618 + SYNB1934SynlogicPhase 2
44
Kuvan®MerckPhase 3
77
Kuvan®MerckApproved
85
SAR444836SanofiPhase 1/2
40
KuvanBioMarin PharmaceuticalPre-clinical
20
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
20
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
49
BMN 307BioMarin PharmaceuticalPhase 1/2
38
SapropterinBioMarin PharmaceuticalPre-clinical
20
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
82
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
49

Other Products from BioMarin Pharmaceutical

NaglazymeApproved
82
saproterin dihydrochlorideApproved
82
Pegvaliase + MethotrexateApproved
82
Kuvan®Approved
82
KuvanApproved
82